T. Campbell

Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients

B. Carleton, R. Marrie, H. Tremlett, 2014, Expert opinion on drug safety.

Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis

R. Marrie, J. Fisk, Tingting Zhang, 2016, Neurology.

THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

T. Campbell, Vladimir Migounov, Stephanie J Wong, 2002 .

Effects of physical comorbidities on disability progression in multiple sclerosis

C. Wolfson, R. Marrie, J. Fisk, 2018, Neurology.

Expression of the inhibitor of apoptosis protein family in multiple sclerosis reveals a potential immunomodulatory role during autoimmune mediated demyelination

M. Holcik, J. Gillard, T. Campbell, 2008, Multiple sclerosis.

Nursing Management of Gastrointestinal Adverse Events Associated With Delayed-Release Dimethyl Fumarate: A Global Delphi Approach

Charles Minor, T. Campbell, M. Namey, 2020, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses.

Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis

C. Ross, B. Carleton, J. Denny, 2018, Nature Genetics.

Psychiatric comorbidity is associated with disability progression in multiple sclerosis

S. Patten, R. Marrie, J. Fisk, 2018, Neurology.

Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study

S. Patten, R. Marrie, J. Fisk, 2016, Multiple sclerosis.